Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, Chiari S, Favalli G, Mangili G, Presti M, et al. Bolis G, et al. Among authors: presti m. Ann Oncol. 1995 Nov;6(9):887-93. doi: 10.1093/oxfordjournals.annonc.a059355. Ann Oncol. 1995. PMID: 8624291 Free article. Clinical Trial.
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, et al. Mangioni C, et al. Among authors: presti m. J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71. doi: 10.1093/jnci/81.19.1464. J Natl Cancer Inst. 1989. PMID: 2674459 Clinical Trial.
Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, Villa A, Conta E, Guarnerio P, Cipriani S, Parazzini F. Bolis G, et al. Among authors: presti m. J Clin Oncol. 2004 Feb 15;22(4):686-90. doi: 10.1200/JCO.2004.03.017. J Clin Oncol. 2004. PMID: 14966092 Free article. Clinical Trial.
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F; Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group. Bolis G, et al. Among authors: presti m. Gynecol Oncol. 2001 Apr;81(1):3-9. doi: 10.1006/gyno.2001.6151. Gynecol Oncol. 2001. PMID: 11277642 Clinical Trial.
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. van Wijk FH, et al. Among authors: presti m. Ann Oncol. 2003 Mar;14(3):441-8. doi: 10.1093/annonc/mdg112. Ann Oncol. 2003. PMID: 12598351 Free article. Clinical Trial.
195 results